A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...
These glasses allow people with macular degeneration to see complete objects by banishing pesky blind spots using dozens of ...
Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...
Germany’s Formycon and its licensing partner Klinge Biopharma have announced that the European Commission (EC) has granted ...
Regulatory ApprovalFormycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / 06:30 CET/CESTThe issuer is solely ...
Hosted on MSN3d
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical TrialOcugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a ...
Another common early symptom is blurry or distorted vision. Straight lines, like those on a doorframe or a tiled floor, may ...
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback